Excellent progress on clinical programs
Lyme Disease Vaccine Candidate VLA15
- Further positive Phase 2 results, including booster response
- Phase 3 expected to commence in the third quarter of 2022
Inactivated COVID-19 Vaccine Candidate VLA2001
- Positive pivotal Phase 3 results
- Purchase Agreements approved by European Commission (EC) and Kingdom of Bahrain for up to 60 million doses and one million doses, respectively, in 2022 and 2023
- Positive homologous booster results between seven to eight months after primary vaccination
- Confirmed neutralization of ancestral virus, Delta and Omicron variants in laboratory studies
- Emergency Use Authorization granted in Bahrain; reviews ongoing with the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA)
Single-Shot Chikungunya Vaccine Candidate VLA1553
- Final positive pivotal Phase 3 results
- Pre-submission process expected to commence in the second quarter of 2022
Strong full-year 2021 revenues and cash position
Total revenues of €348.1 million in 2021 compared to € 110.3 million in 2020, an increase of 216%
- Includes € 94.8 million of product and other revenues (excluding COVID), at the higher end of the Companys previously communicated guidance of € 85 to €100 million, and
- € 253.3 million of COVID-related revenues under the terminated UK agreement
Cash position of € 346.7 million at December 31, 2021
- Reflects $209.6 million of combined gross proceeds from Nasdaq initial public offering (IPO) and European placement in May 2021, plus November 2021 follow-on offering, and
- Pre-payments under the EC COVID-19 vaccine supply agreement
2022 financial guidance
- Total revenues between € 430 to € 590 million expected, including:
- € 350 to € 500 million of COVID-19 vaccine sales subject to regulatory approvals and deliveries of VLA20011
- € 60 to € 70 million of other vaccine sales
- Approximately € 20 million of Other Revenues (revenues from collaborations, licensing and services)
- R&D expenses expected between € 160 million to €200 million
Catch up on all of Valneva's earnings results here.